Your browser doesn't support javascript.
Global challenges in preparedness and response to epidemic infectious diseases.
Olliaro, Piero; Torreele, Els.
  • Olliaro P; ISARIC Global Support Centre, International Severe Acute Respiratory and Emerging Infection Consortium, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, New Richards Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7FZ, UK. Electronic address: piero.olliaro@ndm.ox.ac.uk.
  • Torreele E; Visiting Fellow, Institute for Innovation and Public Purpose, University College London, London, UK.
Mol Ther ; 30(5): 1801-1809, 2022 05 04.
Article in English | MEDLINE | ID: covidwho-1702807
ABSTRACT
Lessons drawn from successes and failures with coronavirus disease 2019 (COVID-19) and Ebola virus disease (EVD) should help shaping a robust health innovation system for infectious disease epidemics. Epidemic response research and development (R&D) can be mobilized quickly for public health priorities and yield medicinal products within months. However, to resolve epidemics, technological advances must be equitably accessible and deployed, and these examples expose the limitations of a supply-driven, fragmented R&D ecosystem relying primarily on the private sector to deliver health products. Efficient epidemic response requires a coordinated public health-focused, end-to-end R&D ecosystem for the development, registration, availability, and use of pharmaceutical products. Because pivotal clinical trials can only be conducted during outbreaks, significant preparation must be done beforehand strengthening clinical research capacity and developing pre-positioned trial protocols and clinical characterization protocols, as well as conducting discovery and pre-clinical research, manufacturing, and early clinical testing of candidate products. This will allow for speedy execution of clinical research early into an outbreak and delivering products within a short time. Effective interventions should be adopted and deployed ensuring equitable access during the ongoing outbreak. Measures to make products available where and when needed must be integrated throughout the R&D value chain.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Communicable Diseases / Hemorrhagic Fever, Ebola / Epidemics / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Mol Ther Journal subject: Molecular Biology / Therapeutics Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Communicable Diseases / Hemorrhagic Fever, Ebola / Epidemics / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Mol Ther Journal subject: Molecular Biology / Therapeutics Year: 2022 Document Type: Article